IL145526A - Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl - Google Patents

Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl Download PDF

Info

Publication number
IL145526A
IL145526A IL145526A IL14552601A IL145526A IL 145526 A IL145526 A IL 145526A IL 145526 A IL145526 A IL 145526A IL 14552601 A IL14552601 A IL 14552601A IL 145526 A IL145526 A IL 145526A
Authority
IL
Israel
Prior art keywords
hdl
enzymotic
lipg
predispositions
vldl
Prior art date
Application number
IL145526A
Original Assignee
Univ Pennsylvania
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by Univ Pennsylvania, Aventis Pharma Inc filed Critical Univ Pennsylvania
Publication of IL145526A publication Critical patent/IL145526A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
IL145526A 1999-03-26 2001-09-20 Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl IL145526A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
PCT/US2000/007870 WO2000057837A2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Publications (1)

Publication Number Publication Date
IL145526A true IL145526A (en) 2010-11-30

Family

ID=23060703

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14552600A IL145526A0 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
IL145526A IL145526A (en) 1999-03-26 2001-09-20 Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL14552600A IL145526A0 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol

Country Status (13)

Country Link
EP (1) EP1171078A4 (en)
JP (1) JP2002540127A (en)
KR (2) KR100887164B1 (en)
AU (1) AU776684B2 (en)
BR (1) BR0009333A (en)
CA (1) CA2363486C (en)
HK (1) HK1043309A1 (en)
IL (2) IL145526A0 (en)
MX (1) MXPA01009727A (en)
NO (2) NO331779B1 (en)
NZ (2) NZ531180A (en)
WO (1) WO2000057837A2 (en)
ZA (1) ZA200107598B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
KR20110091796A (en) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
EP2370579B1 (en) 2008-12-04 2017-03-29 CuRNA, Inc. Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
MX2011005912A (en) 2008-12-04 2011-06-17 Opko Curna Llc Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf.
KR101682735B1 (en) 2009-02-12 2016-12-06 큐알엔에이, 인크. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN102482677B (en) 2009-03-16 2017-10-17 库尔纳公司 Nuclear factor (red blood cell derives 2) sample 2 (NRF2) relevant disease is treated by suppressing NRF2 natural antisense transcript
JP5904935B2 (en) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド Treatment of DLK1-related diseases by suppression of natural antisense transcripts against Delta-like 1 homolog (DLK1)
CA2761152A1 (en) 2009-05-06 2010-11-11 Opko Curna, Llc Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
CA2761142C (en) 2009-05-06 2021-06-08 Opko Curna, Llc Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
ES2618572T3 (en) 2009-05-08 2017-06-21 Curna, Inc. Treatment of diseases related to the dystrophin family by inhibiting a natural antisense transcript for the dmd family
KR101749356B1 (en) 2009-05-18 2017-07-06 큐알엔에이, 인크. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
EP2435571B1 (en) 2009-05-28 2016-12-14 CuRNA, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101801404B1 (en) 2009-06-16 2017-12-20 큐알엔에이, 인크. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
KR101702689B1 (en) 2009-06-16 2017-02-06 큐알엔에이, 인크. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
ES2618894T3 (en) 2009-06-24 2017-06-22 Curna, Inc. TREATMENT OF DISEASES RELATED TO THE RECEIVER OF THE TUMOR NECROSIS FACTOR 2 (TNFR2) BY INHIBITION OF THE ANTISENTED NATURAL TRANSCRIPT FOR TNFR2
CN102482672B (en) 2009-06-26 2016-11-09 库尔纳公司 By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene
JP2013500017A (en) 2009-07-24 2013-01-07 カッパーアールエヌエー，インコーポレイテッド Treatment of sirtuin (SIRT) related diseases by blocking natural antisense transcripts to sirtuin (SIRT)
CN102762731B (en) 2009-08-05 2018-06-22 库尔纳公司 By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
JP6189594B2 (en) 2009-08-11 2017-08-30 クルナ・インコーポレーテッド Treatment of adiponectin (ADIPOQ) -related diseases by suppression of natural antisense transcripts against adiponectin (ADIPOQ)
EP2982755B1 (en) 2009-08-21 2020-10-07 CuRNA, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
EP2470657B1 (en) 2009-08-25 2019-10-23 CuRNA, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
NO2480669T3 (en) 2009-09-25 2018-04-07
RU2639550C2 (en) 2009-12-16 2017-12-21 Курна, Инк. Treatment of diseases connected with site-1 membrane-impacted peptidase of transcription factors (mbtps1), by inhibiting natural antisense transcript to mbtps1
RU2609631C2 (en) 2009-12-23 2017-02-02 Курна, Инк. Treatment of diseases, associated with hepatocyte growth factor (hgf), by inhibition of natural antisense transcript to hgf
EP2515947B1 (en) 2009-12-23 2021-10-06 CuRNA, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
CN102770540B (en) 2009-12-29 2017-06-23 库尔纳公司 P63 relevant diseases are treated by suppressing the natural antisense transcript of oncoprotein 63 (p63)
KR101838305B1 (en) 2009-12-29 2018-03-13 큐알엔에이, 인크. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
US20120289583A1 (en) 2009-12-31 2012-11-15 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
CN102906264B (en) 2010-01-04 2017-08-04 库尔纳公司 IRF8 relevant diseases are treated by suppressing the natural antisense transcript of interferon regulatory factor 8 (IRF8)
WO2011085066A2 (en) 2010-01-06 2011-07-14 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
ES2671877T3 (en) 2010-01-25 2018-06-11 Curna, Inc. Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1
KR101838308B1 (en) 2010-02-22 2018-03-13 큐알엔에이, 인크. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
RU2612884C2 (en) 2010-04-02 2017-03-13 Курна, Инк. Treatment of diseases associated with colonystimulating factor 3 (csf3) by inhibition of natural antisense transcript to csf3
KR101900962B1 (en) 2010-04-09 2018-09-20 큐알엔에이, 인크. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
US9089588B2 (en) 2010-05-03 2015-07-28 Curna, Inc. Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
RU2620978C2 (en) 2010-05-26 2017-05-30 Курна, Инк. Treatment of diseases associated with methionine sulfoxide reductase a (msra), by msra natural antisense transcript inhibition
DK2576783T3 (en) 2010-05-26 2018-03-12 Curna Inc TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
PL2585596T3 (en) 2010-06-23 2021-06-28 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
EP2593547B1 (en) 2010-07-14 2017-11-15 CuRNA, Inc. Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
KR102010598B1 (en) 2010-11-23 2019-08-13 큐알엔에이, 인크. Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
JP6188686B2 (en) 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN)
EA029151B1 (en) 2011-09-06 2018-02-28 Курна, Инк. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF VOLTAGE-GATED SODIUM CHANNELS (SCNxA) WITH SMALL MOLECULES
DK2825648T3 (en) 2012-03-15 2018-10-15 Curna Inc TREATMENT OF BRAIN-DERIVATIVE NEUROTROPHIC FACTOR (BDNF) -related DISEASES BY INHIBITATION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
CN102628060A (en) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 Production method of low-fat milk
EP2915882B1 (en) * 2012-11-05 2018-10-17 Shionogi & Co., Ltd. Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance
SG11201507105RA (en) 2013-03-14 2015-10-29 Shionogi & Co Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
TWI688575B (en) 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
AU2022214429A1 (en) 2021-02-01 2023-09-14 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
EP4378480A1 (en) * 2021-07-26 2024-06-05 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507203A (en) * 1992-12-04 1996-08-06 イノーバー ラボラトリーズ，インコーポレイテッド Regulatable nucleic acid therapies and methods of their use
BR9713847A (en) * 1996-12-06 2000-02-29 Rhone Poulenc Rorer Pharma Isolated polypeptide encoded by a lipase-like gene, composition, pharmaceutical composition, antigenic fragment, isolated nucleic acid, vector, recombinant cell, antibody, hybridoma cell, processes for preparing a polypeptide, to screen agonists or antagonists of llg activity, for the enzymatic hydrolysis of a phosphatidylcholine ester, and to improve the lipid profile in the serum of a human or other animal having an undesirable lipid profile, and, transgenic mouse.
AU1941899A (en) * 1997-12-19 1999-07-12 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Also Published As

Publication number Publication date
WO2000057837A8 (en) 2001-09-27
KR20020029651A (en) 2002-04-19
EP1171078A4 (en) 2002-11-06
BR0009333A (en) 2002-01-08
NO20014657L (en) 2001-11-21
KR100887164B1 (en) 2009-03-10
CA2363486C (en) 2012-12-18
NO331784B1 (en) 2012-03-26
HK1043309A1 (en) 2002-09-13
WO2000057837A9 (en) 2001-10-18
CA2363486A1 (en) 2000-10-05
WO2000057837A2 (en) 2000-10-05
ZA200107598B (en) 2003-05-28
NO20100214L (en) 2001-11-21
NO331779B1 (en) 2012-03-26
NZ531180A (en) 2005-06-24
EP1171078A2 (en) 2002-01-16
AU3918700A (en) 2000-10-16
WO2000057837A3 (en) 2001-01-25
KR20050044812A (en) 2005-05-12
IL145526A0 (en) 2002-06-30
NO20014657D0 (en) 2001-09-25
NZ514350A (en) 2004-12-24
AU776684B2 (en) 2004-09-16
MXPA01009727A (en) 2002-07-22
JP2002540127A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
IL145526A (en) Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl
SG46354A1 (en) Methods of use for inhibiting bone loss and lowering serum cholesterol
PL343269A1 (en) Alpha-ketoamide inhibitors of 20s proteasome
PL343007A1 (en) Inhibitors of phospholipase enzymes
PL342995A1 (en) Inhibitors of phospholipase enzymes
EP1150118A4 (en) Cholesterol sensor and method for determining cholesterol
AU5869000A (en) System and method for performing context switching and rescheduling of a processor
NO20013161L (en) Preparations of ileum-bile acid transport inhibitors and cholesterol ester transfer protein inhibitors for cardiovascular indications
AU1856997A (en) Method for raising hdl cholesterol levels
EP1212065A4 (en) Compositions and methods for raising hdl cholesterol levels
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
AU4955496A (en) Method for determination of cholesterol in low-density lipoprotein or very low-density lipoprotein
AU2002245191A1 (en) Method and system for internet access
AU9537098A (en) 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein
IL141043A (en) Method for detecting viruses using cholesterol
AU6737600A (en) System and method for displaying results of search
EP1149288A4 (en) Process for pan-genomic determination of macromolecular atomic structures
IL132173A (en) System for treatment of waste
EP1009199A4 (en) Method for controlling plasma processor
AU7589598A (en) Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
AU3074099A (en) Method and composition for lowering low density lipoprotein cholesterol
AU2768495A (en) Use of 5-alpha-reductase inhibitors to increase hdl cholesterol levels
AU2177701A (en) Use of hmg-coa reductase inhibitors for treating seborrhea
AU4387700A (en) System and method of internet access and load management
TW368174U (en) Joining structure for silicon steel sheet set of stabilizator

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees